MedCity Influencers

What HEDIS Can’t See in an Asthma Follow-Up Visit

This opportunity that HEDIS has created for patients who were too often discharged and forgotten is well past due — but it’s up to clinicians to take it a step further to figure out why each patient lost control.

For measurement year 2026, NCQA retired the Asthma Medication Ratio, the HEDIS measure that compared controller medications to total asthma medications. The measure only captured patients with persistent asthma, identified through a proxy based on utilization and dispensing. A patient can carry a diagnosis of intermittent asthma and still end up in the emergency department. 

The replacement measure, Follow-Up After Acute and Urgent Care Visits for Asthma (AAF-E), now tracks the share of patients ages 5 to 64 seen in urgent care, the emergency department (ED), an observation stay or an inpatient admission for asthma who then had an outpatient follow-up visit with an asthma diagnosis within 30 days. The measure is an overdue improvement.

The new measure description explains what the follow-up visit should accomplish, including checking whether symptoms have resolved and how the lungs are functioning, assessing risk factors, looking for what triggered the exacerbation, and reviewing or creating a long-term treatment plan. However, there’s a gap: the measure itself only requires that a visit with an asthma diagnosis code took place inside of the 30-day window. 

presented by

In 2022, 42.4% of people with asthma had at least one exacerbation, and asthma accounted for nearly one million ED visits in 2020. A claims analysis from NCQA found less than half of asthma-related ED visits were followed by appropriate outpatient care, with 30-day follow-up rates of 46.1% in commercial populations and just 33.9% in the Medicaid populations. Plans and practices that want lower healthcare costs and drive better patient outcomes need to care as much about what happens in the visit as whether it happens. 

Why what happens in the visit matters

A recent exacerbation is one of the strongest predictors of the next one. In a large U.S. cohort of patients with severe or difficult-to-treat asthma, patients 12 and older with an asthma ED visit or hospitalization in the prior three months had more than six times the odds of a future severe exacerbation over 18 months, and close to four times the odds after adjusting for demographic and clinical factors. In children, a systematic review of six studies covering more than 162,000 children found nearly tenfold odds of another exacerbation after a previous one. 

Follow-up helps, but there is only evidence of modest benefits. A study of more than 90,000 pediatric asthma ED visits found that follow-up within 14 days was linked to fewer return ED visits at one year, 25% versus 28.3%. Earlier studies found no protective effect, or even more ED use among patients who were seen, likely because sicker patients were more likely to get follow-up. A 2025 study following 89,606 working-age asthma patients found that exacerbation frequency drives the economic burden of the disease. Repeat events drive cost, and the 30-day visit is the least expensive place to prevent the next one. 

presented by

What a useful follow-up includes

A new ED visit can indicate that something in the patient’s current care plan isn’t working, even if the patient or their chart suggests that their asthma is controlled. Clinicians should start by reassessing asthma control with a validated assessment tool, such as the Asthma Control Test, rather than relying on how the patient says they feel.

Evaluating if they are adherent to their medication, and, if they are, how they use it and is the next step. There’s a big difference between taking medications and taking them correctly. A systematic review of 144 studies found only 31% of patients with asthma or COPD used correct inhaler technique, and that the rate of incorrect inhaler technique hasn’t improved in decades. If a patient isn’t using their inhaler correctly, it could look like the treatment isn’t working. 

Clinicians should also discuss what happened in the days leading up to and right before their ED visit. A recent viral illness, a new exposure at home or work, smoking or vaping, or a pattern across earlier episodes can all provide context that gets to the root cause of their exacerbation.

Rhinitis, seasonal flares or symptoms tied to a specific room or activity could also mean that the patient has undocumented allergic triggers. The 2020 NAEPP guideline update recommends allergen-specific mitigation for patients with confirmed sensitization and related symptom history, with sensitization confirmed by skin or blood testing. 

If nothing else, clinicians should also reevaluate if the patient’s initial diagnosis is correct, especially in older adults with a smoking history whose charts carry asthma at some visits and COPD at others. An analysis found that 25% to 50% of patients labeled with COPD had no airflow obstruction on post-bronchodilator spirometry, and the authors suggest some may have untreated asthma. Another meta-analysis found asthma overlap in about 27% of COPD patients, with more frequent exacerbations and hospitalizations than either disease alone. Since the two can coexist, the clinician should still consider asthma or allergies even if there is a COPD diagnosis. If there’s still diagnostic uncertainty or repeated ED visits despite treatment, this should prompt a specialist referral. 

Making the visit count

Even though the measure allows for 30 days, the sooner, the better. One health plan’s provider guidance recommends scheduling the follow-up before discharge and aiming for 7 to 14 days. Telehealth visits count for the measure, which helps access, but watching inhaler technique or getting spirometry may require an in-person component. 

For practices, that means building the visit around these questions rather than booking a quick medication check. For plans, it means looking past whether a follow-up claim exists. A claim shows the patient was seen, not if control was reassessed, a trigger identified, or the diagnosis questioned. Taking the time to assess and make necessary changes to the patient’s care plan pays off. In the Inner-City Asthma Study, a home intervention tailored to each child’s sensitizations and exposures reduced symptom days, and a cost analysis found fewer unscheduled clinic visits at a cost of $1,469 per family. 

This opportunity that HEDIS has created for patients who were too often discharged and forgotten is well past due, but it’s up to clinicians to take it a step further to figure out why each patient lost control. The real test of this new 30-day visit measure is whether it changes what happens over the next 12 months and if we see meaningful changes in acute and urgent care visit volume for patients with asthma.

Photo: milan2099, Getty Images

Gary Falcetano, PA, is the U.S. Scientific Affairs Manager for Allergy in ImmunoDiagnostics at Thermo Fisher Scientific. A licensed physician assistant with more than 25 years of diverse experience in emergency and disaster medicine, primary care, and allergy and immunology.

This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.